Details of the Drug Formulation (DFM)
General Information of DFM (ID: F01848) | |||||
---|---|---|---|---|---|
Name |
Atenolol 100 mg tablet
|
||||
Company |
Aidarex Pharmaceuticals; AvKARE; Northwind Pharmaceuticals; NuCare Pharmaceuticals; RemedyRepack; Teva Pharmaceuticals
|
||||
Active Pharmaceutical Ingredient (API) | Atenolol | API Info click to show the detail info of this API | |||
Essential hypertension | ICD-11: BA00 | Approved | |||
Drug Inactive Ingredient (DIGs) | |||||
DIG ID | DIG Info | DIG Name | DIG Functional Class | ||
E01UTP | DIG Info | Magnesium stearate | lubricant | ||
E0FU1S | DIG Info | Vinylpyrrolidone | Binding agent ... | ||
Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM | ||||||
---|---|---|---|---|---|---|
Oxidoreductase (ORase) | ||||||
DBT Name: Albendazole monooxygenase (CYP3A4) | Click to Show/Hide | |||||
Detailed Information | DBT Info click to show the detail info of this DBT | |||||
Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
Interacting DIG | Magnesium stearate | |||||
Biological Activity | Protein expression downregulation (tested by experiment) | [1] | ||||
Tested Species | Homo sapiens (Human) | |||||
UniProt ID | CP3A4_HUMAN | |||||
References | |||||
---|---|---|---|---|---|
1 | Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.